key: cord-0886699-0wpge0gl authors: Lapinsky, Stephen E; Adhikari, Neill KJ title: COVID-19, variants of concern and pregnancy outcome date: 2021-08-03 journal: Obstet Med DOI: 10.1177/1753495x211028499 sha: 6ef70918fb30d71c125d3ccf5e0595a66757452b doc_id: 886699 cord_uid: 0wpge0gl nan travelers from Brazil screened at an airport in Japan. This variant contains additional mutations that may affect its ability to be recognized by antibodies. Three sublineages have been identified of a variant first identified in India in October 2020 (B.671.1). These include B.1.617.2 (variant Delta) and B.1.617.3 (variant Kappa) which have increased significantly since February 2021. The Delta variant appears to be far more transmissible than the Alpha variant, taking over as the predominant variant in many parts of the UK and other countries due to increased transmissibility; investigations of its association with increased disease severity are ongoing. How do these COVID-19 variants impact the pregnant individual? At the beginning of the COVID-19 pandemic, there was considerable concern that pregnant women would experience more severe disease, as has been the case in influenza pandemics 3 as well as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Early reports did not show an increase in mortality among pregnant women, although hospitalizations and ICU admission were increased. 4 More recently, among all studies included in a living systematic review, 5 the risks of ICU admission (4.2% vs. 0.1%) and mortality (0.8% vs. 0.2%) were higher in pregnant women with COVID-19 compared to pregnant women without COVID-19, but the absolute numbers of deaths (n ¼ 16) and ICU admissions (n ¼ 68) informing these comparisons were small. When pregnant women with COVID-19 were compared to non-pregnant women of reproductive age with COVID-19, the risk of mortality was similar (0.3% vs. 0.6%), but the risks of ICU admission, invasive ventilation, and need for extracorporeal membrane oxygenation (ECMO) were increased. Of the 192 studies included in the review, none was from a low-income country and 9 were from lower middle-income countries. A multinational study involving 18 countries including 4 lowmiddle income countries compared pregnancy outcomes between COVID-infected and non-infected pregnant individuals during the period March to October 2020. 6 COVID-19 infection was associated with a substantial increase in severe maternal morbidity and maternal mortality, and neonatal complications. With subsequent waves of COVID-19, several centers have reported increasing numbers of critically ill pregnant women with COVID-19 compared with the first wave. The Royal Brompton Hospital in London, an ECMO referral center, reports the referral of 4 peripartum women (out of 34 referrals for women aged 16-49 years, 12%) for potential ECMO in the first wave (1 March-31 August 2020) and 19 (31% of 62 referrals) in the second wave (1 September 2020-4 March 2021). 7 The Intensive Care National Audit & Research Centre (ICNARC) reports similar findings across the U.K., with the number of peripartum women requiring admission to intensive care increasing from 70 (8.9% of all women aged 16-49 years) in the first wave to 270 (13.5%) in the second wave. 8 Brazil has reported a disproportionately large number of maternal deaths attributed to COVID-19, with an in-hospital mortality rate of 8.3%, with a marked predominance in Black women. 9 Furthermore, reported maternal deaths due to severe acute respiratory illness in Brazil in 2020 were 1.5 times greater than that reported in 2016, likely due to COVID-19 deaths. A study from Spain demonstrates a marked increase in pregnant and postpartum women admitted to hospital in the second wave compared with the first, although no mortality was documented. 10 A UKOSS report compared symptomatic pregnant women admitted to hospital with confirmed COVID-19 during the initial (March to November 2020) and later (December 2020 to February 2021) waves. 11 Women admitted during the later wave when the B.1.1.7 variant became predominant were more likely to require critical care (OR 1.62) and respiratory support (OR 2.58). Our experience in the ICU at Mount Sinai Hospital, Toronto, a large referral obstetric unit, is very similar: 5 pregnant women with COVID-19 were admitted between March 2020 and January 2021, increasing to 14 women between March and May 2021, corresponding with the third wave in Canada which was predominated by the B.1.1.7 (Alpha) VOC. The largest study of African patients, critically ill patients with COVID-19, enrolled 3140 patients and found a 48.2% risk of hospital mortality (to 30 days), which was 11%-23% higher than the non-African global risk. 12 This study did not report data on pregnant women but given that the excess mortality was likely driven in part by limited resources, outcomes from pregnant women would be expected to be similar. Could this dramatic apparent increase in the risk of critical illness with COVID-19 in subsequent waves of infection be related to increased pathogenicity of the VOCs in the pregnant woman, or is it simply a reflection of increased total number of COVID infections in younger individuals? Currently, there are no data to answer this question. The consistent difference between the first and later waves seems to suggest a change in pathogenicity in pregnant women, but this requires further study. What is evident, however, is that COVID-19 is not the benign disease in pregnancy that initial experience led us to hope. Although in some high-income countries, successful vaccination programs have dramatically reduced the burden of COVID-19 infection, in most of the world the pandemic continues as a major public health crisis. Pregnant women are now recognized as a highrisk subgroup and are at significant risk in areas least able to provide high-level supportive care. Limited data suggest that vaccination in pregnancy is safe, 13 and this vulnerable group needs to be a priority in global vaccination programs. Variants of the virus that causes COVID-19 World Health Organization. Tracking SARS-CoV-2 variants Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and metaanalysis Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID Multinational Cohort Study. JAMA Pediatr. Epub ahead of print 22 Were pregnant women more affected by COVID-19 in the second wave of the pandemic? Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland COVID-19 poses alarming pregnancy and postpartum mortality risk in Brazil First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus Females in Hospital with SARS-CoV-2 infection, the association with pregnancy and pregnancy outcomes: a UKOSS/ISARIC/CO-CIN investigation African COVID-19 Critical Care Outcomes Study (ACCCOS) Investigators. Patient care and clinical outcomes for patients with COVID-19 infection admitted to African high-care or intensive care units (ACCCOS): a multicentre, prospective, observational cohort study Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons Both authors contributed to writing this manuscript. Stephen E Lapinsky https://orcid.org/0000-0002-6930-0306 Neill KJ Adhikari https://orcid.org/0000-0003-4038-5382